Motor unit number estimate as a predictor of motor dysfunction in an animal model of type 1 diabetes

Am J Physiol Endocrinol Metab. 2009 Sep;297(3):E602-8. doi: 10.1152/ajpendo.00245.2009. Epub 2009 Jul 14.

Abstract

Peripheral neuropathy is a common complication of diabetes that leads to severe morbidity. In this study, we investigated the sensitivity of motor unit number estimate (MUNE) to detect early motor axon dysfunction in streptozotocin (STZ)-treated mice. We compared the findings with in vitro changes in the morphology and electrophysiology of the neuromuscular junction. Adult Thy1-YFP and Swiss Webster mice were made diabetic following three interdaily intraperitoneal STZ injections. Splay testing and rotarod performance assessed motor activity for 6 wk. Electromyography was carried out in the same time course, and compound muscle action potential (CMAP) amplitude, latency, and MUNE were estimated. Two-electrode voltage clamp was used to calculate quantal content (QC) of evoked transmitter release. We found that an early reduction in MUNE was evident before a detectable decline of motor activity. CMAP amplitude was not altered. MUNE decrease accompanied a drop of end-plate current amplitude and QC. We also observed small axonal loss, sprouting of nerve endings, and fragmentation of acetylcholine receptor clusters at the motor end plate. Our results suggest an early remodeling of motor units through the course of diabetic neuropathy, which can be readily detected by the MUNE technique. The early detection of MUNE anomalies is significant because it suggests that molecular changes associated with pathology and leading to neurodegeneration might already be occurring at this stage. Therefore, trials of interventions to prevent motor axon dysfunction in diabetic neuropathy should be administered at early stages of the disorder.

Publication types

  • Evaluation Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / analysis
  • Cell Count / methods
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / diagnosis
  • Diabetes Mellitus, Experimental / pathology
  • Diabetes Mellitus, Type 1 / chemically induced
  • Diabetes Mellitus, Type 1 / complications*
  • Diabetes Mellitus, Type 1 / diagnosis
  • Diabetes Mellitus, Type 1 / pathology
  • Diabetic Neuropathies / blood
  • Diabetic Neuropathies / diagnosis*
  • Diabetic Neuropathies / pathology
  • Diabetic Neuropathies / physiopathology
  • Early Diagnosis
  • Electric Stimulation
  • Electrophysiology / methods
  • Hyperglycemia / chemically induced
  • Hyperglycemia / complications
  • Mice
  • Mice, Transgenic
  • Motor Neuron Disease / blood
  • Motor Neuron Disease / diagnosis*
  • Motor Neuron Disease / etiology
  • Motor Neuron Disease / pathology
  • Motor Neurons / pathology*
  • Motor Neurons / physiology
  • Muscle, Skeletal / innervation
  • Muscle, Skeletal / pathology
  • Muscle, Skeletal / physiopathology
  • Neuromuscular Junction / pathology
  • Neuromuscular Junction / physiopathology
  • Prognosis
  • Streptozocin
  • Time Factors

Substances

  • Blood Glucose
  • Streptozocin